Body & Brain | Science News

SUPPORT SCIENCE NEWS

Science News is a nonprofit.

Help us keep you informed.


News in Brief

Body & Brain

Coffee may limit prostate cancer, plus protecting organ transplants and limiting HIV transmission in this week’s news

By
3:41pm, May 20, 2011

Drug limits kidney rejection
The anti-leukemia drug alemtuzumab (Campath) can lessen the risk of immune rejection in some people receiving a kidney transplant, a new study finds. But the results, published in the May 19 New England Journal of Medicine, suggest that the drug doesn’t improve prospects for the patients most prone to rejecting a transplant. Researchers at several U.S. medical facilities enrolled 139 such high-risk patients and 335 low-risk patients to get either alemtuzumab or standard drugs after a kidney transplant. Three years later, 85 percent of low-risk recipients getting alemtuzumab and 76 percent of those on standard medication had survived with no rejection. Among the high-risk group, these percentages were 76 and 70, a difference that could be due to chance. —Nathan Seppa

 

Drugs limit HIV transfer
By taking drugs to suppress HIV, an infe

This article is only available to Science News subscribers. Already a subscriber? Log in now. Or subscribe today for full access.

Get Science News headlines by e-mail.

More from Science News

From the Nature Index Paid Content